Selecta Biosciences (NASDAQ:SELB) released its earnings results on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.08, MarketWatch Earnings reports.
Shares of Selecta Biosciences stock traded down $0.29 during trading hours on Friday, reaching $5.51. 347,760 shares of the company’s stock were exchanged, compared to its average volume of 238,999. Selecta Biosciences has a fifty-two week low of $4.74 and a fifty-two week high of $16.55. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. The company has a market cap of $120.49 million, a price-to-earnings ratio of -1.72 and a beta of 0.91.
A number of research firms have issued reports on SELB. UBS Group set a $6.00 target price on Selecta Biosciences and gave the stock a “hold” rating in a report on Friday. BidaskClub downgraded shares of Selecta Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Zacks Investment Research downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Mizuho restated a “buy” rating and set a $30.00 price objective on shares of Selecta Biosciences in a research note on Wednesday, October 17th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $23.83.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/10/selecta-biosciences-selb-issues-earnings-results.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.